Cargando…

Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial

OBJECTIVE: The objective of this study is to evaluate if gonadotropin-releasing hormone agonist (GnRHa) trigger is a better alternative to human chorionic gonadotropin (hCG) in polycystic ovary syndrome (PCOS) of Indian origin undergoing in vitro fertilization (IVF) cycles with GnRH antagonist for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishna, Deepika, Dhoble, Snehal, Praneesh, Gautham, Rathore, Suvarna, Upadhaya, Amit, Rao, Kamini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070398/
https://www.ncbi.nlm.nih.gov/pubmed/27803584
http://dx.doi.org/10.4103/0974-1208.192056
_version_ 1782461138569527296
author Krishna, Deepika
Dhoble, Snehal
Praneesh, Gautham
Rathore, Suvarna
Upadhaya, Amit
Rao, Kamini
author_facet Krishna, Deepika
Dhoble, Snehal
Praneesh, Gautham
Rathore, Suvarna
Upadhaya, Amit
Rao, Kamini
author_sort Krishna, Deepika
collection PubMed
description OBJECTIVE: The objective of this study is to evaluate if gonadotropin-releasing hormone agonist (GnRHa) trigger is a better alternative to human chorionic gonadotropin (hCG) in polycystic ovary syndrome (PCOS) of Indian origin undergoing in vitro fertilization (IVF) cycles with GnRH antagonist for the prevention of ovarian hyperstimulation syndrome (OHSS). DESIGN: Prospective randomized control trial. SETTING: Tertiary care center. MATERIALS AND METHODS: A total of 227 patients diagnosed with PCOS, undergoing IVF in an antagonist protocol were recruited and randomly assigned into two groups: Group A (study group): GnRHa trigger 0.2 mg (n = 92) and Group B (control group): 250 μg of recombinant hCG as trigger (n = 101) 35 h before oocyte retrieval. We chose segmentation strategy, freezing all embryos in both the groups. STATISTICAL ANALYSIS: Continuous variables were expressed as mean ± standard deviation independent sample t-test and Kolmogorov-Smirnov test were used for continuous variables which were normally distributed and Mann-Whitney U-test for data not normally distributed. MAIN OUTCOME MEASURES: Primary outcome: OHSS (mild, moderate, and severe) rates. Secondary outcomes: Maturity rate of the oocytes, fertilization rate, availability of top quality embryos on day 3 (Grade 1 and Grade 2). RESULTS: The incidence of moderate to severe OHSS in the hCG group was 37.6% and 0% in the GnRHa group with P < 0.001. The GnRHa group had significantly more mature oocytes retrieved (19.1 ± 11.7 vs. 14.1 ± 4.3), more fertilized oocytes (15.6 ± 5.6 vs. 11.7 ± 3.6), and a higher number of top quality cleavage embryos on day 3 (12.9 ± 4.7 vs. 7.5 ± 4.3) than the hCG group. CONCLUSIONS: The most effective strategy which significantly eliminates the occurrence of OHSS in PCOS following ovarian stimulation in antagonist IVF cycles is the use of GnRHa trigger yielding more mature oocytes and good quality embryos when compared with hCG trigger.
format Online
Article
Text
id pubmed-5070398
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-50703982016-11-01 Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial Krishna, Deepika Dhoble, Snehal Praneesh, Gautham Rathore, Suvarna Upadhaya, Amit Rao, Kamini J Hum Reprod Sci Original Article OBJECTIVE: The objective of this study is to evaluate if gonadotropin-releasing hormone agonist (GnRHa) trigger is a better alternative to human chorionic gonadotropin (hCG) in polycystic ovary syndrome (PCOS) of Indian origin undergoing in vitro fertilization (IVF) cycles with GnRH antagonist for the prevention of ovarian hyperstimulation syndrome (OHSS). DESIGN: Prospective randomized control trial. SETTING: Tertiary care center. MATERIALS AND METHODS: A total of 227 patients diagnosed with PCOS, undergoing IVF in an antagonist protocol were recruited and randomly assigned into two groups: Group A (study group): GnRHa trigger 0.2 mg (n = 92) and Group B (control group): 250 μg of recombinant hCG as trigger (n = 101) 35 h before oocyte retrieval. We chose segmentation strategy, freezing all embryos in both the groups. STATISTICAL ANALYSIS: Continuous variables were expressed as mean ± standard deviation independent sample t-test and Kolmogorov-Smirnov test were used for continuous variables which were normally distributed and Mann-Whitney U-test for data not normally distributed. MAIN OUTCOME MEASURES: Primary outcome: OHSS (mild, moderate, and severe) rates. Secondary outcomes: Maturity rate of the oocytes, fertilization rate, availability of top quality embryos on day 3 (Grade 1 and Grade 2). RESULTS: The incidence of moderate to severe OHSS in the hCG group was 37.6% and 0% in the GnRHa group with P < 0.001. The GnRHa group had significantly more mature oocytes retrieved (19.1 ± 11.7 vs. 14.1 ± 4.3), more fertilized oocytes (15.6 ± 5.6 vs. 11.7 ± 3.6), and a higher number of top quality cleavage embryos on day 3 (12.9 ± 4.7 vs. 7.5 ± 4.3) than the hCG group. CONCLUSIONS: The most effective strategy which significantly eliminates the occurrence of OHSS in PCOS following ovarian stimulation in antagonist IVF cycles is the use of GnRHa trigger yielding more mature oocytes and good quality embryos when compared with hCG trigger. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5070398/ /pubmed/27803584 http://dx.doi.org/10.4103/0974-1208.192056 Text en Copyright: © Journal of Human Reproductive Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Krishna, Deepika
Dhoble, Snehal
Praneesh, Gautham
Rathore, Suvarna
Upadhaya, Amit
Rao, Kamini
Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
title Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
title_full Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
title_fullStr Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
title_full_unstemmed Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
title_short Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial
title_sort gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in pcos undergoing ivf cycles for an ohss free clinic: a randomized control trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070398/
https://www.ncbi.nlm.nih.gov/pubmed/27803584
http://dx.doi.org/10.4103/0974-1208.192056
work_keys_str_mv AT krishnadeepika gonadotropinreleasinghormoneagonisttriggerisabetteralternativethanhumanchorionicgonadotropininpcosundergoingivfcyclesforanohssfreeclinicarandomizedcontroltrial
AT dhoblesnehal gonadotropinreleasinghormoneagonisttriggerisabetteralternativethanhumanchorionicgonadotropininpcosundergoingivfcyclesforanohssfreeclinicarandomizedcontroltrial
AT praneeshgautham gonadotropinreleasinghormoneagonisttriggerisabetteralternativethanhumanchorionicgonadotropininpcosundergoingivfcyclesforanohssfreeclinicarandomizedcontroltrial
AT rathoresuvarna gonadotropinreleasinghormoneagonisttriggerisabetteralternativethanhumanchorionicgonadotropininpcosundergoingivfcyclesforanohssfreeclinicarandomizedcontroltrial
AT upadhayaamit gonadotropinreleasinghormoneagonisttriggerisabetteralternativethanhumanchorionicgonadotropininpcosundergoingivfcyclesforanohssfreeclinicarandomizedcontroltrial
AT raokamini gonadotropinreleasinghormoneagonisttriggerisabetteralternativethanhumanchorionicgonadotropininpcosundergoingivfcyclesforanohssfreeclinicarandomizedcontroltrial